PL1725528T3 - Sulfonylopirole jako inhibitory HDAC - Google Patents

Sulfonylopirole jako inhibitory HDAC

Info

Publication number
PL1725528T3
PL1725528T3 PL05716989T PL05716989T PL1725528T3 PL 1725528 T3 PL1725528 T3 PL 1725528T3 PL 05716989 T PL05716989 T PL 05716989T PL 05716989 T PL05716989 T PL 05716989T PL 1725528 T3 PL1725528 T3 PL 1725528T3
Authority
PL
Poland
Prior art keywords
sulphonylpyrroles
hdac inhibitors
hdac
inhibitors
Prior art date
Application number
PL05716989T
Other languages
English (en)
Inventor
Thomas Maier
Thomas Beckers
Thomas Baer
Petra Gimmnich
Frank Dullweber
Matthias Vennemann
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of PL1725528T3 publication Critical patent/PL1725528T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
PL05716989T 2004-03-11 2005-03-10 Sulfonylopirole jako inhibitory HDAC PL1725528T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04101003 2004-03-11
PCT/EP2005/051086 WO2005087724A2 (en) 2004-03-11 2005-03-10 Sulphonylpyrroles as hdac inhibitors
EP05716989.8A EP1725528B1 (en) 2004-03-11 2005-03-10 Sulphonylpyrroles as hdac inhibitors

Publications (1)

Publication Number Publication Date
PL1725528T3 true PL1725528T3 (pl) 2013-12-31

Family

ID=34928899

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05716989T PL1725528T3 (pl) 2004-03-11 2005-03-10 Sulfonylopirole jako inhibitory HDAC

Country Status (25)

Country Link
US (5) US7842820B2 (pl)
EP (2) EP2272827A1 (pl)
JP (1) JP4856623B2 (pl)
KR (1) KR101130556B1 (pl)
CN (1) CN1926103B (pl)
AR (1) AR048427A1 (pl)
AU (1) AU2005221834B2 (pl)
BR (1) BRPI0508464B8 (pl)
CA (1) CA2558552C (pl)
CY (1) CY1114284T1 (pl)
DK (1) DK1725528T3 (pl)
EA (1) EA012451B1 (pl)
ES (1) ES2430371T3 (pl)
HR (1) HRP20130810T1 (pl)
IL (1) IL177168A (pl)
ME (1) ME02122B (pl)
NO (1) NO337457B1 (pl)
NZ (1) NZ549251A (pl)
PL (1) PL1725528T3 (pl)
PT (1) PT1725528E (pl)
RS (1) RS52937B (pl)
SI (1) SI1725528T1 (pl)
TW (1) TWI353977B (pl)
WO (1) WO2005087724A2 (pl)
ZA (1) ZA200606315B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
PL1725528T3 (pl) * 2004-03-11 2013-12-31 4Sc Ag Sulfonylopirole jako inhibitory HDAC
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
CA2599538C (en) * 2005-03-15 2013-07-30 Nycomed Gmbh N-sulphonylpyrroles and their use as histone deacetylase inhibitors
CA2603398A1 (en) * 2005-04-07 2006-10-12 Nycomed Gmbh Sulfonylpyrroles as histone deacetylase inhibitors
NZ541788A (en) * 2005-08-11 2007-12-21 Auckland Uniservices Ltd Conducting polymers and their use in oligonucleotide (ODN) probes
ES2381962T3 (es) * 2005-09-21 2012-06-04 4Sc Ag Nuevos sulfonilpirroles como inhibidores de las HDAC
AU2006298881A1 (en) 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
BRPI0520806A2 (pt) * 2005-12-27 2009-06-09 Ct Nac De Investigaciones Oncologicas derivados pirrólicos, processos para a preparação de compostos, seu uso e composição farmacêutica que os contém
EP2100878A1 (en) 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
ES2605815T3 (es) * 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
CN101941948A (zh) * 2009-07-10 2011-01-12 南开大学 点击化学合成具有分支结构的组蛋白去乙酰酶抑制剂
EP3524324A1 (en) 2011-02-28 2019-08-14 BioMarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10188756B2 (en) 2013-10-18 2019-01-29 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN105801464B (zh) * 2014-12-29 2019-05-28 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
WO2017178577A1 (en) 2016-04-14 2017-10-19 4Sc Ag Medical application of resminostat in asian patients
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療
WO2019200238A1 (en) 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
CA3097087A1 (en) 2018-04-17 2019-10-24 4Sc Ag Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment
TW202114659A (zh) 2019-10-02 2021-04-16 德商４Ｓｃ製藥公司 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
WO1993012075A1 (fr) 1991-12-10 1993-06-24 Shionogi & Co., Ltd. Derive d'acide hydroxamique a base de sulfonamide aromatique
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP1233958B1 (en) * 1999-11-23 2011-06-29 MethylGene Inc. Inhibitors of histone deacetylase
JP2003514905A (ja) 1999-11-23 2003-04-22 メルク エンド カムパニー インコーポレーテッド ピラジノン系トロンビン阻害薬
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
BR0211810A (pt) * 2001-08-09 2004-08-24 Ono Pharmaceutical Co Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
JP3795044B2 (ja) 2001-09-14 2006-07-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
MXPA04007775A (es) * 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
JP2006512306A (ja) 2002-08-29 2006-04-13 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション アリール及びヘテロアリールプロペンアミド、それらの誘導体並びにそれらの治療用途
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
CA2553513A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
PL1725528T3 (pl) 2004-03-11 2013-12-31 4Sc Ag Sulfonylopirole jako inhibitory HDAC
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
GB2415703A (en) 2004-07-02 2006-01-04 Hewlett Packard Development Co Liquid crystal display device
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US7432808B2 (en) 2004-12-15 2008-10-07 Intel Corporation Wireless module enabled component carrier for parts inventory and tracking
WO2006066197A1 (en) 2004-12-17 2006-06-22 Janssen Pharmaceutica, N.V. Tetrahydroisoquinoline compounds for treatment of cns disorders
CA2599538C (en) * 2005-03-15 2013-07-30 Nycomed Gmbh N-sulphonylpyrroles and their use as histone deacetylase inhibitors
CA2603398A1 (en) * 2005-04-07 2006-10-12 Nycomed Gmbh Sulfonylpyrroles as histone deacetylase inhibitors
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
ES2381962T3 (es) * 2005-09-21 2012-06-04 4Sc Ag Nuevos sulfonilpirroles como inhibidores de las HDAC
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts

Also Published As

Publication number Publication date
DK1725528T3 (da) 2013-09-02
ME02122B (me) 2014-02-28
EP1725528A2 (en) 2006-11-29
EA012451B1 (ru) 2009-10-30
ES2430371T3 (es) 2013-11-20
US20070184979A1 (en) 2007-08-09
WO2005087724A3 (en) 2005-12-08
US7842820B2 (en) 2010-11-30
US20100261721A1 (en) 2010-10-14
NO337457B1 (no) 2016-04-18
RS52937B (sr) 2014-02-28
AU2005221834A1 (en) 2005-09-22
EP1725528B1 (en) 2013-05-29
AR048427A1 (es) 2006-04-26
SI1725528T1 (sl) 2013-11-29
TWI353977B (en) 2011-12-11
IL177168A0 (en) 2006-12-10
CN1926103A (zh) 2007-03-07
BRPI0508464A (pt) 2007-07-31
CA2558552C (en) 2015-06-02
IL177168A (en) 2012-03-29
CY1114284T1 (el) 2016-08-31
WO2005087724A2 (en) 2005-09-22
NZ549251A (en) 2010-05-28
BRPI0508464B1 (pt) 2020-02-11
HRP20130810T1 (en) 2013-09-30
JP4856623B2 (ja) 2012-01-18
ZA200606315B (en) 2008-02-27
PT1725528E (pt) 2013-09-26
KR20060131927A (ko) 2006-12-20
JP2007527902A (ja) 2007-10-04
CA2558552A1 (en) 2005-09-22
KR101130556B1 (ko) 2012-03-30
HK1102583A1 (en) 2007-11-30
EA200601587A1 (ru) 2007-04-27
TW200538432A (en) 2005-12-01
AU2005221834B2 (en) 2010-09-30
BRPI0508464B8 (pt) 2021-05-25
US8969401B2 (en) 2015-03-03
CN1926103B (zh) 2012-12-19
US8067615B2 (en) 2011-11-29
NO20064418L (no) 2006-12-08
US20130079347A1 (en) 2013-03-28
US20100261761A1 (en) 2010-10-14
US8399505B2 (en) 2013-03-19
US20110166140A1 (en) 2011-07-07
EP2272827A1 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
PL1725528T3 (pl) Sulfonylopirole jako inhibitory HDAC
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL197752A0 (en) Hdac inhibitors
IL179398A0 (en) Dpp-ib inhibitors
ZA200801394B (en) Novel sulphonylpyrroles as inhibitors of HDAC S novel sulphonylpyrroles
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
ZA200608221B (en) Thiadlazolidinones as GSK-3 Inhibitors
IL184303A0 (en) Amino-pyridines as inhibitors of ??-secretase
ZA200802867B (en) Fap inhibitors
IL179280A0 (en) Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
EP1756092A4 (en) NEW INHIBITORS OF RHO-KINASEN
GB0415663D0 (en) Compound
EP1732560A4 (en) SUBSTITUTED CINNOLINE-4-YLAMINE
IL180888A0 (en) Substituted n-acyl-2-aminothiazoles
GB0408771D0 (en) Compound
GB0421355D0 (en) Inhibitors
GB0624187D0 (en) HDAC inhibitors
GB0515327D0 (en) Comt inhibitors
GB0421356D0 (en) Inhibitors
GB0411562D0 (en) Compound
GB0425969D0 (en) Compound
ZA200700723B (en) Substituted N-acyl-2-aminothiazoles
GB0516967D0 (en) Inhibitors
GB0408300D0 (en) Novel inhibitors